Positioning AQUILA Among Early-Intervention Strategies for High-Risk Smoldering Multiple Myeloma

This segment places the AQUILA trial in the context of prior early-intervention studies in high-risk smoldering multiple myeloma. Faculty compare AQUILA with earlier trials such as QuiRedex, E3A06, and CENTAURUS, highlighting key differences in study design, patient selection, treatment approach, and duration of follow-up.

The discussion focuses on how AQUILA addressed limitations of earlier studies through a larger sample size, more consistent high-risk definitions, fixed-duration therapy, and the use of subcutaneous daratumumab. Panelists reflect on how these design elements contributed to the robustness and interpretability of the trial results.

By contrasting AQUILA with prior evidence, this segment helps clarify why the study represents an important step forward in the early-intervention landscape and provides perspective on how emerging data may influence future clinical research and practice considerations.